Evaluating these options with a professional can ensure the best outcome
Session Information Date: Sunday, October 26, 2025 Title: (04300469) Rheumatoid Arthritis Diagnosis, Manifestations, and Outcomes Poster I Session Type: Poster Session A Session Time: 10:30AM-12:30PM Background/Purpose: Obesity significantly increases cardiovascular morbidity and mortality in rheumatoid arthritis (RA), yet effective strategies for managing obesity-related risks in this population remain limited
Toxin and drug exposure Some also hypothesise that toxin exposure could trigger ME/CFS (61), such as organophosphate compounds (152, 153) and heavy metals (154)
They are signs the drug is working on your gut motility and your central nervous system appetite pathways simultaneously
In 2014, Saxenda was the first GLP-1 introduced specifically for chronic weight management, followed by Wegovy in 2021 and Zepbound in 2023